Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3231-3239

  Luganini, Anna ^a   Nicoletto, Silvia Fabiole ^b   Pizzuto, Lorena ^b   Pirri, Giovanna ^b   Giuliani, Andrea ^b   Landolfo, Santo ^a   Gribaudo, Giorgio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Spider Biotech Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CELL SURFACE PROTEIN; DENDRIMER; HEPARAN SULFATE; PEPTIDE 103; PEPTIDE DERIVATIVE; PEPTIDE SB101; PEPTIDE SB102; PEPTIDE SB104; PEPTIDE SB105; PEPTIDE SB105 A10; PEPTIDE SB106; PEPTIDE SB107; PEPTIDE SB109; PEPTIDE SB110; PEPTIDE SB111; PEPTIDE SB112; PEPTIDE SB113; PROTEOGLYCAN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; EMBRYO; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION PREVENTION; LUNG FIBROBLAST; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN STRUCTURE; TARGET CELL; VERO CELL; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS ATTACHMENT; VIRUS INACTIVATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; DENDRIMERS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOBLOTTING; PEPTIDES; VERO CELLS; VIRUS REPLICATION;

EID: 79959252926     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00149-11     Document Type: Article

References (39)

1. Berk, A. J. 2007. Adenoviridae: the viruses and their replication, p. 2355-2394. In D. M. Knipe et al. (ed.), Fields virology, 5th ed., vol. 2. Lippincott, Williams & Wilkins, Philadelphia, PA.
2. Bernstein, D. I., et al. 2003. Evaluation of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob. Agents Chemother. 47:3784-3788.
3. Bishop, J. R., M. Schuksz, and J. D. Esko. 2007. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446:1030-1037.
4. Bourne, N., et al. 2000. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob. Agents Chemother. 44:2471-2474.
5. Campadelli-Fiume, G., et al. 2007. The multipartite system that mediates entry of herpes simplex virus into the cell. Rev. Med. Virol. 17:313-326.
6. Caposio, P., A. Luganini, G. Hahn, S. Landolfo, and G. Gribaudo. 2007. Activation of the virus-induced IKK/NF-κB signaling axis is critical for the replication of human cytomegalovirus in quiescent cells. Cell. Microbiol. 9:2040-2054.
7. Cloninger, M. J. 2002. Biological applications of dendrimers. Curr. Opin. Chem. Biol. 6:742-748.
8. Coen, D. M., and P. A. Schaffer. 2003. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat. Rev. Drug Discov. 2:278-288.
9. Reference deleted.
10. Donalisio, M., et al. 2010. Identification of a dendrimeric heparan sulfatebinding peptide that inhibits infectivity of genital types of human papillomaviruses. Antimicrob. Agents Chemother. 54:4290-4299.
11. Gong, E., et al. 2005. Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex virus. Antiviral Res. 68:139-146. (Pubitemid 41612458)
12. Greco, A., J.-J. Diaz, D. Thouvenot, and F. Morfin. 2007. Novel targets for the development of anti-herpes compounds. Infect. Disord. Drug Targets 7:11-18.
13. Heegaard, P. M., and U. Boas. 2006. Dendrimer based anti-infective and anti-inflammatory drugs. Recent Pat. Antiinfect. Drug Discov. 1:331-351.
14. Jenssen, H. 2005. Anti herpes simplex virus activity of lactoferrin/lactoferricin - an example of antiviral activity of antimicrobial protein/peptide. Cell. Mol. Life. Sci. 62:3002-3013.
15. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
16. Keller, M. J., A. Tujama, M. J. Carlucci, and B. C. Herold. 2005. Topical microbicides for prevention of genital herpes infection. J. Antimicrob. Chemother. 55:420-423.
17. Laquerre, S., et al. 1998. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J. Virol. 72:6119-6130. (Pubitemid 28283402)
18. Luganini, A., P. Caposio, S. Landolfo, and G. Gribaudo. 2008. Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry. Antimicrob. Agents Chemother. 52:1111-1120.
19. Luganini, A., et al. 2010. Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate. Antiviral Res. 85:532-540.
20. Lyles, D. S., and C. E. Rupprecht. 2007. Rhabdoviridae, p. 1363-1408. In D. M. Knipe et al. (ed.), Fields virology, 5th ed., vol. 1. Lippincott, Williams & Wilkins, Philadelphia, PA.
21. McCarthy, T. D., et al. 2005. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2:312-318.
22. Niederhafner, P., et al. 2005. Peptide dendrimers. J. Pept. Sci. 11:757-788.
23. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
24. Oyan, A. M., et al. 1993. Resistance of herpes simplex virus type 2 to neomycin maps to the N-terminal portion of glycoprotein C. J. Virol. 67: 2434-2441. (Pubitemid 23118836)
25. Pauwels, R., et al. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20: 309-321.
26. Pini, A., et al. 2005. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob. Agents Chemother. 49:2665-2672.
27. Pini, A., et al. 2007. Characterization of the branched antimicrobial peptide M6 by analyzing its mechanism of action and in vivo toxicity. J. Pept. Sci. 13:393-399.
28. Pinna, D., et al. 2008. Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide. Antimicrob. Agents Chemother. 52:3078-3084.
29. Prichard, M. N., and C. Jr., Shipman. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205.
30. Roizman, B., D. M. Knipe, and R. J. Whitley. 2007. Herpes simplex viruses, p. 2501-2601. In D. M. Knipe et al. (ed.), Fields virology, 5th ed., vol. 2. Lippincott, Williams & Wilkins, Philadelphia, PA.
31. Rosa Borges, A., and C.-L. Schengrund. 2005. Dendrimers and antivirals: a review. Curr. Drug Targets Infect. Disord. 5:247-254.
32. Rupp, R., S. L. Rosenthal, and L. R. Stanberry. 2007. VivaGel (SPL7013 gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int. J. Nanomed. 2:561-566.
33. Schuksz, M., et al. 2008. Surfen, a small molecule antagonist of heparan sulfate. Proc. Natl. Acad. Sci. U. S. A. 105:13075-13080.
34. Shieh, M., D. WuDunn, R. Montgomery, J. Esko, and P. Spear. 1992. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J. Cell Biol. 116:1273-1281.
35. Shogan, B., et al. 2006. Virucidal activity of a GT-rich oligonucleotide against herpes simplex virus mediated by glycoprotein B. J. Virol. 80:4740-4747.
36. Silvestri, M. E., and V. A. Sundqvist. 2001. An investigation into the heparinbinding properties of a synthetic peptide deduced from antigenic domain 2 of human cytomegalovirus glycoprotein B. Scand. J. Immunol. 53:282-289.
37. Spear, P. G. 2004. Herpes simplex virus: receptors and ligands for cell entry. Cell. Microbiol. 6:401-410.
38. Superti, F., M. G. Ammendolia, and M. Marchetti. 2008. New advances in anti-HSV chemotherapy. Curr. Med. Chem. 15:900-911.
39. Whitley, R. 2006. New approaches to the therapy of HSV infections. Herpes 13:53-55. (Pubitemid 44299023)